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Background: The personality dimensions neuroticism and extraversion likely represent part of the
vulnerability to depression. The stability over longer time periods of these personality dimensions in
depressed patients treated with psychological treatment or medication and in untreated persons with
depression in the general population remains unclear. Stability of neuroticism and extraversion in treated
and untreated depressed persons would suggest that part of the vulnerability to depression remains
stable over time. The current study addressed the question whether treatment in depressed patients is
related to changes in neuroticism and extraversion.
Methods: Data are from 709 patients with major depressive disorder participating in a cohort study
(Netherlands Study of Depression and Anxiety; NESDA). We determined the 2-year stability of
extraversion and neuroticism in treated and untreated persons and related change in depression severity
to change in personality over time.
Results: Neuroticism decreased from baseline to 2-year follow-up (d¼0.73) in both treated and
untreated persons. Extraversion did not change signiﬁcantly after controlling for neuroticism and
depression severity at baseline and follow-up. Decreased depressive symptoms over time were related
to decreased neuroticism (d¼1.91) whereas increased depressive symptoms over time were unrelated to
neuroticism (d¼0.06).
Limitations: Patients were not randomized to treatment conditions and the groups are therefore not
directly comparable.
Conclusions: Treated patients with depression in the general population improve just as much on
depression severity and neuroticism as untreated persons with depression. This suggests that changes in
neuroticism in the context of treatment likely represent mood-state effects rather than direct effects of
treatment.
& 2013 Elsevier B.V. All rights reserved.1. Introduction
The relation between Major Depressive Disorder (MDD) and
the personality dimensions of neuroticism and extraversion has
been studied in clinical settings and in population based studies
(for an overview: Kotov et al., 2010). These studies have shown
that MDD is positively associated with neuroticism and negativelyll rights reserved.
.nl (F. Renner).with extraversion. Moreover, clinical and population based studies
have identiﬁed neuroticism as an important vulnerability factor
for MDD (Boyce et al., 1991; Fanous et al., 2007; Hettema et al.,
2006; Hirschfeld et al., 1989; Kendler et al., 2006; Kendler et al.,
2004; Ormel et al., 2004), whereas low extraversion appears to be
associated only weakly to MDD (Kendler et al., 2006).
While neuroticism and extraversion likely represent part of the
vulnerability to MDD, they are also known to change with the
current mood state. For example, Karsten et al. (2012) used data
from the Netherlands Study of Depression and Anxiety (NESDA;
Penninx et al., 2008) and found that the occurrence of a depressive
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decrease in extraversion (Karsten et al., 2012). Similarly recovery
from a depressive disorder was associated with decreased neuro-
ticism and increased extraversion (Karsten et al., 2012), suggesting
that neuroticism and extraversion are mood state dependent. In
this study treatment status was not taken into account so it
remains unclear whether treatment is related to the observed
changes in neuroticism and extraversion.
The stability of neuroticism and extraversion in patients with
MDD has also been studied in the context of randomized clinical
trials (RCTs) and in naturalistic treatment studies (Berlim et al.,
2013; Ekselius and von Knorring, 1999; Hellerstein et al., 2000;
Tang et al., 2009). Studying the stability of neuroticism and
extraversion in the context of RCTs is important to determine
which aspects of treatment are related to change in persona-
lity. Tang et al. (2009), for example, showed that neuroticism
decreased and extraversion increased in patients with MDD taking
selective serotonin reuptake inhibitors (SSRIs) compared to
patients taking a pill placebo. Interestingly, change in person-
ality did not depend on improvement from depressive symp-
toms suggesting that change in personality is not a mere
epiphenomenon of improved depressive state (Tang et al.,
2009). In a naturalistic treatment study it has been shown that
a 4-week trial of high frequency repetitive transcranial magnetic
stimulation was related to decreased levels of neuroticism at
post-treatment and the authors suggested that these improve-
ments in neuroticism were likely independent from improve-
ments in depressive state (Berlim et al., 2013). These ﬁndings
suggest that treatment for MDD may have an impact on the
personality of patients with MDD independent of the impact of
treatment on depression itself.
In RCTs comparing the impact of depression treatment on
change in personality the control condition usually consists of a
placebo group (e.g., Ekselius and von Knorring, 1999; Hellerstein
et al., 2000; Tang et al., 2009) but patients assigned to placebo
usually also experience substantial symptom reduction. To more
directly test whether treatment for depression is related to change
in personality it is necessary to compare treated and untreated
persons with depression. This can be done in population based
studies because not all depressed persons in the general popula-
tion seek treatment.
Another issue that has not been addressed in RCTs is the long-
term stability of personality in treated and untreated persons with
depression. Assessing the long term stability of personality traits
in depressed patients is important because stability of personality
traits in the context of change in depressive state would suggest
that part of the vulnerability to depression remains intact, increas-
ing the risk for subsequent relapse. For example, in a recent meta-
analysis of longitudinal studies it has been shown that personality
and personality disorders remain relatively stable over time and
that patients under treatment for various mental disorders do not
report more change in personality than non-patients (Ferguson,
2010). Such ﬁndings suggest that part of the vulnerability, in terms
of the underlying personality, remains stable over longer periods
of time in depressed patients in the general population, regardless
of treatment status.
When studying the stability of personality in treated and
untreated persons with depression in the general population some
differences between RCTs and population based studies should be
taken into account. In RCTs patients usually receive highly effective
treatments under optimal conditions, whereas at the population
level many depressed patients do not always receive adequate
health care (Kessler et al., 2003; Young et al., 2001). Moreover,
patients with MDD in RCTs might differ from patients with MDD in
the general population on a number of clinically relevant variables
such as comorbidity.The present study draws data from the Netherlands Study of
Depression and Anxiety (NESDA), to determine the 2-year stability
of neuroticism and extraversion in patients treated with psycho-
logical treatment and/or antidepressant medication and in
untreated persons with depression. Moreover, we sought to relate
in both untreated and treated persons the change in depressive
symptoms over time to change in neuroticism and extraversion
over time. The following questions were addressed in this study:
(1) Is treatment in patients with MDD at the population level
related to change in neuroticism and extraversion? (2) Are changes
in depressive symptoms over time in untreated and treated
persons with depression related to changes in neuroticism and
extraversion?2. Methods
2.1. Sample
The present report is based on data from an ongoing long-
itudinal cohort study, the Netherlands Study of Depression and
Anxiety (NESDA; N¼2981). This ongoing multi-site cohort study
determines predictors, course and consequences of depression
and/or anxiety disorders in the Netherlands. Participants were
healthy controls, persons with remitted depressive and/or anxiety
disorders and persons with a current depressive and/or anxiety
disorder. Participants were recruited from primary care (n¼1610),
secondary care (n¼807) and from the general population
(n¼564). General exclusion criteria of NESDA were a primary
diagnosis of psychotic, obsessive compulsive, bipolar or severe
addiction disorder. Participants who were not ﬂuent in Dutch were
also excluded. The NESDA study protocol was centrally approved
by an Institutional Review Board and locally by the review
boards of all participating sites and all participants signed written
informed consent. A more detailed description of the NESDA study
is available elsewhere (Penninx et al., 2008).
The current study used data from the baseline assessment, the
one year follow-up assessment (FU1) and the 2-year follow-up
assessment (FU2). Psychopharmaca use was assessed at baseline at
FU1 and at FU2 and coded according to the Anatomical Therapeu-
tic Chemical (ATC) classiﬁcation system (WHO, 2007). Patients
who took any of the following medications when entering the
study or during the study period were excluded from the analyses:
antipsychotics (ATC code: N05A), anxiolytics (ATC code: N05B),
hypnotics or sedatives (ATC code: N05C), psychostimulants (ATC
code: N06B), or anti-dementia drugs (ATC code: N06D) Patients
taking any of these drugs during the study period were excluded
from the analyses because we aimed to study change in person-
ality in untreated and treated persons receiving treatment for
depression and not for anxiety or other disorders. Of the overall
NESDA sample of 2981 participants, 1115 (37.4%) had a diagnosis
of current MDD (6-month recency) at baseline. Of these 1115
patients, 393 (35%) were excluded from the analyses because they
reported to have used one of the drugs above in the time period
under study. Therefore, 722 patients with MDD were further
considered for this study, of whom 13 persons had missing
follow-up data, leading to an ultimate 709 persons with MDD as
the ﬁnal study sample.
2.2. Treatment status
Treatment status was deﬁned by the use of antidepressant
medication (ADM) and by self-reported contact with a psycholo-
gist or psychiatrist at any time between baseline and FU2. Patients
who received treatment (psychological or medication) at base-
line were also classiﬁed as treated. ADM use was assessed by
F. Renner et al. / Journal of Affective Disorders 150 (2013) 201–208 203self-report questionnaires and by inspection of drug containers
that participants brought to the baseline and 2-year FU interview
and classiﬁed according to the World Health Organization ATC
classiﬁcation system (WHO, 2007). Psychological treatment was
assessed by the Trimbos/iMTA questionnaire for costs associated
with psychiatric illness (TIC-P; Hakkaart-van Roijen, 2002) and
deﬁned as self-reported contact with a psychologist, psychiatrist
or contact with a secondary care facility. To identify participants as
treated no restrictions were placed on the number of contacts with
a psychological health care provider. Based on these criteria, 520




The Composite International Diagnostic Interview (CIDI) is a
fully structured interview based on the Diagnostic and Statistical
Manual of Mental Disorders (4th ed; DSM–IV; American Psychiatric
Association, 1994) criteria (World Health Organization, 1997).
Excellent inter-rater reliability and validity has been reported for
the CIDI (Andrews and Peters, 1998; Wittchen, 1994). In the NESDA
study, the CIDI was used to determine the presence of current and
lifetime mood disorders, anxiety disorders and alcohol abuse or
dependence. The CIDI was conducted at baseline and at FU2.
2.3.2. IDS-SR
The Inventory of Depressive Symptoms Self-Report version
(IDS-SR; Rush et al., 1996) is a 30-item self-report questionnaire
measuring depressive symptom severity over the past seven days.
Excellent internal consistency (Cronbach's alpha 0.92) and high
correlations with the Hamilton Rating Scale for Depression
(Hamilton, 1960) have been reported (Rush et al., 2003). In the
current study the IDS-SR was obtained at baseline, FU1, and at FU2.
2.3.3. Neo-FFI
The revised NEO Five-Factor Inventory (NEO-FFI) is a widely
used self-report instrument designed to measure the following
higher order personality traits: neuroticism, extraversion, open-
ness to experience, agreeableness, and conscientiousness (Costa
and McCrae, 1995). Good internal consistency (Cronbach's alpha
range 0.87–0.92) has been reported for the domain scales (Costa
and McCrae, 1992). Although in the NESDA study all ﬁve subscales
of the NEO-FFI have been assessed, the present report focuses on
the neuroticism and extraversion scales because these two scales
have most consistently been associated with depression. In the
current study, the NEO-FFI was obtained at baseline and at FU2.2.4. Statistical analyses
SPSS version 19 forWindows was used for statistical analyses. First,
we computed Pearson correlations between depressive symptom
severity and personality dimensions at baseline to determine con-
current relations. Pearson correlations between neuroticism at base-
line and neuroticism at FU2 and between extraversion at baseline and
extraversion at FU2 in treated and untreated persons were computed
as an index of stability of these personality traits over time.
Multilevel Modeling (MLM) was used to predict change in
depressive symptom severity and change in neuroticism and
extraversion over time as a function of treatment status. MLM of
longitudinal data has several advantages above ordinary least
square regression analyses because it can deal with missing data
and include time varying covariates in the analyses. Model build-
ing was guided by the following analytic procedure: First weadded time as a predictor to the model (Model 1). In this model a
signiﬁcant main effect of time indicates that the dependent
variables changes across the various assessment moments. Next
we added treatment status and the interaction between treatment
status and time as predictors (Model 2). In this model a signiﬁcant
time treatment status interaction indicates that change in the
dependent variable over time is different for treated and untreated
persons. Following this we added personality scores as predictors
to the model of change in depression severity and we added
depression severity scores as predictors to the models of change in
neuroticism and extraversion (Model 3). Finally we added the
potential confounding variables gender, age, level of education and
recruitment setting (Final Model). To compare the ﬁt between the
various models we compared change in deviance using a χ² test
with 1 degree of freedom.
We also determined the relation between change in personality
and change in depression severity in treated and untreated
persons. To test whether change in personality predicts change
in depressive symptom severity we added the neuroticism (at
baseline and FU2) x time interaction and the extraversion (at
baseline and FU2) time interaction as predictors to the model of
change in depressive symptom severity. To test whether the
relation between change in personality and change in depressive
symptom severity depends on treatment status, we also added the
neuroticism (at baseline and FU2) time treatment status and
the extraversion time treatment status three-way interactions
to the model predicting change in depressive symptom severity. In
these analyses neuroticism and extraversion were included as time
varying covariates.
To test whether change in depressive symptom severity pre-
dicts change in personality, we conducted two separate MLM
analyses, one with change in neuroticism as dependent variable
and one with change in extraversion as dependent variable. To
determine whether change in depressive symptoms predicts
change in personality we entered the depressive symptoms
(at baseline and FU2) time interaction and the depressive symp-
toms (at baseline and FU2) time treatment status three-way
interaction as predictor variables in both analyses. In these models,
depressive symptoms severity was entered as time varying
covariate.
In all models, continuous independent predictors were stan-
dardized by subtracting the sample mean from the individual
score and dividing the result by the standard deviation of the
mean to facilitate the interpretability of various predictors that are
measured on different scales. In all MLMs we used an unstructured
covariance structure for repeated measures over time and a
Maximum Likelihood estimation method in order to be able to
compare model ﬁt. We computed effects sizes (Cohens' d) for all
models based on estimates from the multi-level analyses (Feingold,
2009). Time was coded as follows: 0¼baseline, 1¼FU1, 2¼FU2.
Treatment seeking was centered and coded −0.5¼untreated and
0.5¼treated.3. Results
3.1. Sample characteristics
Demographic and clinical characteristics of the treated and the
untreated group are shown in Table 1. Depressive symptom
severity at baseline was signiﬁcantly higher in the treated group
(M¼31.46, SD¼11.92) compared to the untreated group
(M¼28.91, SD¼11.47). Baseline levels of extraversion were sig-
niﬁcantly higher in the untreated group (M¼36.87, SD¼7.16)
compared to the treated group (M¼34.88, SD¼6.99). It should
be noted that these statistical differences are not necessarily
Table 1
Demographic and clinical characteristics at baseline for treated and untreated persons.
Characteristic Treated (n¼520) Untreated (n¼189) t Chi-square
Mean (SD) N (%) Mean (SD) N (%)
Age (years) 39.95 (11.69) – 38.80 (12.77) – −1.16 –
Female – 337 (64.1) – 138 (70.4) – 2.56
Education level (years) 11.86 (3.27) – 11.70 (3.16) – −0.57 –
Number of previous episodesa 5.21 (10.13) – 6.16 (11.63) – 1.04 –
Recurrent MDD – 280 (53.2) – 113 (57.7) – 1.13
Anxiety disorder – 330 (62.7) – 114 (58.2) – 1.26
Depressive symptom severity 31.46 (11.92) – 28.91 (11.47) – −2.53* –
Neuroticism 42.08 (6.59) – 41.05 (6.84) – −1.81 –
Extraversion 34.88 (6.99) – 36.87 (7.16) – 2.72** –
n po0.05.
nn po0.01.
a Median number of previous episodes was two in the overall sample, in the treatment seeking group and in the non treatment seeking group.
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differences can reach statistical signiﬁcance. To estimate the
clinical meaningfulness of these differences we also compute the
effect size (Cohens' d) of the differences between the groups. The
effect size of the difference between the groups was 0.22 for
depression severity and 0.28 for extraversion, reﬂecting small
effects (Cohen, 1988). The two groups also differed with respect
to source of recruitment. The majority of people in the treated
group were recruited from secondary care facilities (60.4%),
followed by recruitment from primary care facilities (33.3%) and
by recruitment from the general population (6.3%). Most people
from the untreated group were recruited from primary care
facilities (58.2%) followed by recruitment from secondary care
facilities (26.5%) and by recruitment from the general population
(15.3%). Gender was equally distributed among the two groups.
3.2. Concurrent relations between depressive symptom severity and
the personality dimensions neuroticism and extraversion
At baseline, neuroticism correlated positively with depressive
symptom severity (r¼0.56; po0.001) and negatively with extra-
version (r¼−0.50; po0.001); extraversion correlated negatively
with depressive symptom severity (r¼−0.45; po0.001).
3.3. Modeling change in depressive symptom severity, neuroticism
and extraversion
3.3.1. Change in depressive symptom severity
First, we modeled change in depressive symptom severity over
time by treatment status using MLM. Table 2 summarizes the
results of the four most informative models. In all models there
was a signiﬁcant main effect of time (po0.01) indicating that
depressive symptoms decreased over time (d¼0.89). In the ﬁnal
model, there was a signiﬁcant main effect of time (F(1, 547.75)¼
216.83, po0.001), after adjusting for neuroticism and extraversion
levels and other potential confounding variables. The interac-
tion between time and treatment status was not signiﬁcant
(F(1, 547.74)¼3.39, p¼0.07), suggesting that decrease in depres-
sive symptoms did not depend on treatment status (Fig. 1A).3.3.2. Stability of neuroticism and extraversion
To determine the stability of the personality dimensions neuroti-
cism and extraversion over time in the two groups, we ﬁrst deter-
mined Pearson correlations between neuroticism and extraversion at
baseline and neuroticism and extraversion at FU2. In both groups,
neuroticism at baseline correlated moderately and statisticallysigniﬁcant with neuroticism levels at FU 2 (untreated: r¼0.64,
po0.001; treated r¼0.59, po0.001) and the correlation coefﬁcients
of the two groups did not differ statistically signiﬁcantly, z¼0.78,
p¼0.43. Extraversion at baseline also correlated moderately and
statistically signiﬁcant with extraversion at FU2 in both groups
(untreated: r¼0.77, po0.001; treated: r¼0.72, po0.001) and the
correlation coefﬁcients did not differ between groups, z¼1.10, p¼0.27.
The overall stability coefﬁcient between extraversion at baseline and
extraversion at FU2 (r¼0.74) was stronger than the stability coefﬁcient
between neuroticism at baseline and neuroticism at FU2 (r¼0.60;
z¼3.99, p o0.001).3.3.3. Mean level stability of neuroticism and extraversion
Both groups experienced a statistically signiﬁcant decrease in
mean neuroticism levels from baseline to FU2 (mean decrease
untreated: −4.23, po0.001; mean decrease treated: −3.68,
po0.001) and a statistically signiﬁcant increase in the mean level
of extraversion (mean increase untreated: 1.67; po0.001; mean
increase treated: 1.68; po0.001). To compare the mean level
change in neuroticism and extraversion in the current sample
with a non-depressed control group, we also calculated the mean
level stability of persons in the same study (Penninx et al., 2008)
without any depressive or anxiety disorders (N¼652). Mean
neuroticism levels in the non-depressed group also decreased
statistically signiﬁcantly from baseline to FU2 (mean decrease:
−1.44, po0.001) as did the mean level of extraversion (mean
decrease: −1.32; po0.001). The mean decrease in neuroticism in
the non-depressed group statistically signiﬁcantly differed from
the mean decrease in the untreated (t-(714)¼3.50, po0.001) and
the treated group (t(1032)¼4.74, po0.001). The mean difference
in extraversion in the non-depressed group also statistically
signiﬁcantly differed from the mean difference in extraversion in
the untreated (t(714)¼3.18, po0.01) and treated group (t(1032)¼
5.79, po0.001).
Next we modeled change in neuroticism and extraversion over
time as a function of treatment status using MLM (Table 3). In all
models, predicting change in neuroticism over time there was a
signiﬁcant main effect of time (po0.01), indicating that neuroticism
decreased over time (d¼0.73). In the ﬁnal model the signiﬁcant main
effect of time remained after controlling for depressive symptom
severity and extraversion levels and for potential confounding vari-
ables F(1, 474.05)¼92.45, po0.001. The interaction between time and
treatment status was not signiﬁcant (F(1, 464.61)¼0.40, p¼0.53),
indicating that decrease in neuroticism did not differ between treated
and untreated persons (Fig. 1 B).
In the initial model predicting change in extraversion over time
there was a signiﬁcant main effect of time (po0.01) indicating
Table 2
Predicting change in depressive symptom severity over time.
Parameter Model 1 Model 2 Model 3a Final Modelb
Intercept 28.74 (0.49)** 27.58 (0.59)** 28.45 (0.50)** 29.32 (1.08)**
Time −4.35 (0.23)** −4.06 (0.28)** −4.06 (0.28)** −4.06 (0.28)**
Treatment status – 3.92 (1.18)** 1.71 (0.99) 2.06 (0.98)*
Time treatment status – −1.00 (0.55) −1.01 (0.55) −1.02 (0.55)
−2 log likelihood 11,693.205 11,682.059 11,335.160 11,299.817
Δ deviance – 11.14** 346.90** 35.34**
Note: All continuous predictor variables were standardized before entered into the model.
n po0.05
nn po0.01.
a Adjusted for neuroticism and extraversion at baseline and at FU2.
b Adjusted for potential confounding variables: gender, age, level of education and recruitment setting.
Fig. 1. Two-year course of depressive symptoms, neuroticism and extraversion for
treated and untreated persons with depression. Note. Y-axis presents ﬁxed
predicted values of depression, neuroticism and extraversion course for treated
(n¼520) and untreated (n¼189) persons with MDD.
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for neuroticism and depression severity at baseline and follow-up
change in extraversion over time was not signiﬁcant anymore(F(1, 512.51)¼0.01, p¼0.91). The interaction between time and
treatment status was also not signiﬁcant (F(1, 478.23)¼2.13,
p¼0.15), indicating that extraversion remained stable over time
in both treated and untreated persons (Fig. 1C).
3.4. Differences in change in depression severity and personality
between different types of treatment
To test whether change in depressive symptom severity, neur-
oticism or extraversion differed between different types of
treatment (medication, psychotherapy, or both medication and
psychotherapy) we added dummy coded variables for the different
types of treatment to the ﬁnal multilevel models. In these analyses
the untreated group was used as the reference condition. There
were no differences between type of treatment and change in
depressive symptom severity, change in neuroticism or change in
extraversion (all p-values 40.05).
3.5. Relation between change in personality and change
in depression severity
In the model predicting change in depressive symptom severity
over time, the neuroticism time treatment status and the extr-
aversion time treatment status three-way interactions were
not signiﬁcant (F(1, 550.42)¼0.48, p¼0.49 and F(1, 549.68)¼
1.67, p¼0.20, respectively). Therefore, we removed the non-
signiﬁcant three-way interactions from the model and the model
was rerun. The interactions between time and neuroticism and the
interaction between time and extraversion were not signiﬁcant (F
(1, 734.65)¼0.22, p¼0.64 and F(1, 667.54)¼0.15, p¼0.70, respec-
tively), indicating that change in personality over time did not
predict change in depressive symptom severity over time.
In the model predicting change in neuroticism over time the
depressive symptom severity time treatment status interaction
was not signiﬁcant (F(1, 549.64)¼0.20, p¼0.66) and was therefore
removed from the model. There was a signiﬁcant interaction
between depressive symptom severity and time, F(1, 683.96)¼
25.89, po0.001. To interpret the interaction term, we plotted the
neuroticism total scores at baseline and at FU2 separately for the
low- and high change in depressive symptom severity groups
(Fig. 2), deﬁned as one SD below and above the mean change in
depressive symptom severity. Patients in the high change group
(n¼82) reported a mean decrease of 27.70 (SD¼6.04) on the IDS
whereas patients in the low change group (n¼76) reported a
mean increase of 5.93 (SD¼3.63) on the IDS. As can be seen in
Fig. 2, persons in the high decrease in depressive symptoms group
signiﬁcantly decreased on neuroticism from baseline to FU2
whereas increased depressive symptoms were unrelated to
changes in neuroticism from baseline to FU2 (ES within decrease
Table 3
Predicting change in the personality dimensions neuroticism and extraversion over time.
Parameter Neuroticism Extraversion
Model 1 Model 2 Model 3a Final Modelb Model 1 Model 2 Model 3c Final Modeld
Intercept 41.27 (0.30)** 40.82 (0.38)** 41.24 (0.30)** 41.06 (0.68)** 33.80 (0.32)** 34.43 (0.40)** 34.44 (0.34)** 34.87 (0.79)**
Time −3.65 (0.30)** −3.71 (0.37)** −3.21 (0.33)** −3.18 (0.33)** 1.53 (0.23)** 1.36 (0.29)** 0.03 (0.27) −0.05 (0.27)
Treatment status – 1.51 (0.75)* −0.03 (0.60) −0.08 (0.58) – −2.13 (0.79)** −0.98 (0.67) −0.98 (0.66)
Time treatment status – 0.20 (0.73) 0.40 (0.66) 0.42 (0.66) – 0.57 (0.57) 0.94 (0.50) 0.64 (0.50)
−2 log likelihood 6250.052 6245.145 5854.975 5795.704 6054.320 6047.172 5735.104 5693.581
Δ deviance – 4.907* 390.17** 59.271** – 7.15** 312.07** 41.25**
Note: All continuous predictor variables were standardized before entered into the model.
n po0.05.
nn po0.01.
a Adjusted for depressive symptom severity at all time points and for extraversion at baseline and FU2.
b Adjusted for potential confounding variables: gender, age, level of education, recruitment setting.
c Adjusted for depressive symptom severity at all time points and for neuroticism at baseline and FU2.
d Adjusted for potential confounding variables: gender, age, level of education, recruitment setting.
Fig. 2. Interaction between change in neuroticism over time and change in
depressive symptom severity.
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depressive symptoms group: d¼0.06).
In the model predicting change in extraversion over time the
depressive symptom severity time treatment status interaction
was not signiﬁcant (F(1, 546.24)¼0.99, p¼0.32) and was therefore
removed from the model. After removing the non-signiﬁcant
three-way interaction from the model, the interaction between
depressive symptom severity and time was not signiﬁcant,
F(1, 650.31)¼1.69, p¼0.19, indicating that change in depressive
symptoms did not predict change in extraversion.4. Discussion
The aim of this study was to determine the 2-year stability of
neuroticism and extraversion in treated and untreated persons
with major depressive disorder (MDD) in the general population.
We determined the stability of depressive symptom severity,
neuroticism and extraversion over a period of 2 years in depressed
patients who sought treatment for mental health problems during
the study period and in depressed persons who did not. Depres-
sive symptom severity and neuroticism scores signiﬁcantly
decreased statistically during the study period regardless of
treatment status. These ﬁndings are in line with previous ﬁndings
from the NESDA study showing that depressive symptoms
decrease over time regardless of treatment status (Penninx et al.,
2011) and with ﬁndings from another cohort study in the Nether-
lands showing that treated depressed patients in primary care
have similar outcomes than unrecognized depressed patients notreceiving treatment (Kamphuis et al., 2012). Contrary to our
ﬁndings an earlier cohort study found that treated depressed
patients have better outcomes than untreated persons with
depression (Angst, 1998) whereas in another population based
study it has been shown that treated depressed patients had
worse outcome than untreated persons with depression (Wang,
2004). It should be noted that our ﬁnding that treatment status
was not related to change in depression, neuroticism and extra-
version over time does not suggest that receiving treatment does
not impact these variables. Treated and untreated persons in this
study were not randomized and the effect of a given treatment on
change in depression severity and personality traits can only be
determined in randomized trials because observational studies
suffer from confounding by indication when comparing treated
and non-treated patients.
It has been shown previously, in the context of RCTs, that
depression treatment is related to decreases in neuroticism
(Ekselius and von Knorring, 1999; Hellerstein et al., 2000; Tang
et al., 2009). However, previous studies determined the short-term
stability of neuroticism over a course of depression treatment
with SSRIs whereas the current study determined the long term
(2-year) stability of neuroticism and extraversion in treated and
untreated persons with depression in the general population.
Another explanation for the discrepant ﬁndings, as suggested by
one of the anonymous reviewers, is that the current study did not
differentiate between speciﬁc types of antidepressants whereas
previous RCTs focused speciﬁcally on SSRIs. It is possible that SSRIs
have stronger effects on changes in neuroticism than other types
of antidepressants. Determining the speciﬁc impact of different
types of antidepressants on changes in neuroticism and other
personality traits requires randomization to different types of
antidepressants and is therefore an issue for future RCT based
studies.
We also determined relations between change in depressive
symptom severity and change in personality in treated and
untreated persons with depression and found that change in
depression was associated with change in neuroticism inde-
pendently of treatment status. Patients experiencing strong
symptom reduction reported more decrease in neuroticism
over time compared to patients experiencing an increase in
depressive symptoms over time (Fig. 2). Moreover, changes in
neuroticism and extraversion were not associated with changes
in depressive symptoms. This ﬁnding suggests that changes
in depressive state might drive changes in the underlying
personality rather than the other way around, which is in line
with ﬁndings showing that neuroticism and extraversion in
depressed patients are mood-state dependent (Karsten et al.,
F. Renner et al. / Journal of Affective Disorders 150 (2013) 201–208 2072012). It should be noted, however, that the current research
design and analytic approach does not allow drawing any
causal conclusions. Identifying the causal directions of the
relation between changes in personality and depression is thus
an issue for future research.4.1. Limitations
The ﬁndings of this study should be interpreted in the light of
several limitations. First, patients in this study were not rando-
mized to treatment conditions and might therefore not be directly
comparable. Persons in the treated and in the untreated group
differed with respect to severity of depressive symptoms and
extraversion scores at baseline. Therefore any differences between
the two groups cannot be solely attributed to treatment status.
Second we did not assess treatment adequacy. It should be noted
however that a previous NESDA study found that treatment
adequacy was unrelated to improvement in depressive symptoms
(Prins et al., 2011). Third, we homogenized the sample by exclud-
ing patients who took medication not directly related to depres-
sion (including anxiolytics) during the study period. This might
limit the generalizability of our ﬁndings to depressed patients with
more diverse symptoms. Fourth, we determined cross-sectional
relations between change in depression levels and change in
personality. Given that in the present analysis personality was
only assessed at two time points we could not determine any
temporal relations between change in depression severity and
change in personality. Finally, we did not determine the stability of
other personality dimensions in treated and untreated persons.
It has been shown in a previous NESDA study that the personality
dimension of conscientiousness also changes with depressive state
(Karsten et al., 2012).4.2. Implications
Despite these limitations the results of this study have several
implications for clinical settings and future research. We found
that in a large sample of patients with MDD, treatment status was
unrelated to change in neuroticism and extraversion. We also
found that change in depression predicted change in neuroticism
rather than the other way around. These ﬁndings suggest that
changes in neuroticism might be driven by improved depressive
state (the mood-state effect) rather than by receiving treatment
for depression. From a clinical point of view this suggests that
treatment for depression should focus on depressive symptoms
rather than on the underlying personality structure because
treating the underlying personality structure of depressed patients
might not improve depressive symptom severity. Future research
studying the stability of personality in the context of treatment
should also take into account untreated persons with MDD who
improve in depression severity in order to be able to distinguish
mood-state effects from more direct effects of treatment on
personality. Given that in our study the treated group differed
from the untreated group with respect to several clinical and
demographic variables it is not possible to draw any conclusions
regarding the causal effect of treatment status on change in
neuroticism and extraversion. Future research should determine
characteristics of depressed persons in the general population who
proﬁt from seeking treatment for depression with respect to
changes in neuroticism and extraversion. Finally, in line with what
has previously been reported in the NESDA sample (Karsten et al.,
2012) our ﬁnding that neuroticism changes with depressive state
suggest that personality assessment is partly clouded by the
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